Sanna Jousi of Diaceutics assesses the financial benefits of integrating the planning, analytical and action steps for successful development and commercialization of testing into targeted therapies.
The Return On Investment of Better CDx Planning Based on Early PD-L1 Observations in NSCLC
The Return On Investment of Better CDx Planning Based on Early PD-L1 Observations in NSCLC
4 April, 2019